USPTO and WIPO Publish NimbuDerm™ Patent Applications

Gainesville, Florida - October 14, 2009 - Quick-Med Technologies, Inc. (OTCBB: QMDT), a pioneer in advanced antimicrobial technologies for medical and consumer applications, announced today that the United States Patent and Trademark Office and the World Intellectual Property Organization have published Company patent applications covering Disinfectant Alcohol-Soluble Quaternary Ammonium Polymers.

These patent applications, which have been assigned the United States Patent and Trademark Office Publication Number US2009/0246165 A1 and the International Publication Number WO 2009/089346 A3, disclose the innovative technology of a durable disinfectant that can be bonded to various surfaces. The technology was initially developed to provide highly effective, long-lasting protection on skin, thus overcoming a shortcoming common to most hand sanitizers. However, the applicability of the technology and the associated patent applications are very broad-based in terms of both product applications and the selection of material forms that it produces. The invention covered by this US patent application had previously been published by WIPO as WO2007/024973 A1.

"Quick-Med’s NimbuDerm technology has the potential to dramatically change the handhygiene paradigm by combining the immediate disinfection power of an instant sanitizer with the long-lasting antimicrobial persistence of an advanced bio-active polymer," declared Dr. Jerry Olderman, Vice President of Research & Development. "With many infections being transferred via hand contact, we believe NimbuDerm's third-generation technology could bring a new level of hand-hygiene assurance to consumers and healthcare professionals alike" he observed.

Laboratory tests demonstrate that NimbuDerm's unique antimicrobial polymer properties will kill more than 99.99% of disease causing germs, including the lethal strain of MRSA. Human use tests show that NimbuDerm also provides the same high level of continuing antimicrobial protection for 6 hours after each application without wearing off or losing its effectiveness. Poor hand hygiene is considered to be a major contributor to the increase in MRSA infections. MRSA, which has been identified in hospitals for 4 decades, is now increasingly found in schools, gymnasiums, and offices, and on common "touch surfaces" such as keyboards, door knobs, desktops, telephones and shopping cart handles. MRSA is becoming increasingly problematic, not only in acute care settings, but also in long-term care facilities and the community.

The material which is both colorless and odorless can be produced in such forms as gels, films, fibers, foams, sealants, tubes, rods, sheets, powders and surface impregnations. Other product applications covered by the pending patents include a number of medical devices such as catheters, tubing and wound dressings. Also included are such applications as adhesives, hard surface protective coatings and human or animal skin sanitizers.

About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing innovative technologies for the healthcare and consumer markets. For more information, see: www.quickmedtech.com.

For additional further information, please contact QMT:

J. Ladd Greeno, CEO
Tel. (888) 835.2211 Ext 102
Email: lgreeno@quickmedtech.com

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology is intended to identify forward-looking statements involve risks and uncertainties, including launch and approval of the potential products described herein and the Company¹s results of operations. The Company is also subject to other risks as detailed from time-to-time in the Company¹s SEC filings.